UK markets close in 4 hours 5 minutes
  • FTSE 100

    7,008.27
    +44.94 (+0.65%)
     
  • FTSE 250

    22,228.21
    +158.90 (+0.72%)
     
  • AIM

    1,228.23
    +3.39 (+0.28%)
     
  • GBP/EUR

    1.1617
    -0.0009 (-0.08%)
     
  • GBP/USD

    1.4080
    +0.0028 (+0.20%)
     
  • BTC-GBP

    36,062.13
    +827.07 (+2.35%)
     
  • CMC Crypto 200

    1,407.70
    +19.79 (+1.43%)
     
  • S&P 500

    4,112.50
    +49.46 (+1.22%)
     
  • DOW

    34,021.45
    +433.79 (+1.29%)
     
  • CRUDE OIL

    64.66
    +0.84 (+1.32%)
     
  • GOLD FUTURES

    1,836.20
    +12.20 (+0.67%)
     
  • NIKKEI 225

    28,084.47
    +636.46 (+2.32%)
     
  • HANG SENG

    28,027.57
    +308.90 (+1.11%)
     
  • DAX

    15,311.20
    +111.52 (+0.73%)
     
  • CAC 40

    6,337.32
    +48.99 (+0.78%)
     

The global AMD and other retinal disease drugs market accounted for US$xx billion in 2020

ReportLinker
·4-min read

Forecasts by Product (Lucentis, Eylea, Avastin, Visudyne, Others), by Indication (AMD, Diabetic, Macular, Edema, Diabetic, Retinopathy, Retinal Vein, Occlusion, Others), by End-User (Hospital Pharmacy, Retail, Pharmacy, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios

New York, April 15, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2021-2031" - https://www.reportlinker.com/p06061829/?utm_source=GNW


The global AMD and other retinal disease drugs market accounted for US$xx billion in 2020 and is expected to grow at a CAGR of xx% during the forecast period to reach US$xx billion by 2031. Growing investment in drug R&D by pharmaceutical and biopharmaceutical companies, rising prevalence of retinal diseases, mounting demand for biologics & biosimilars, and developing healthcare infrastructure in emerging economies are some of the major factors that propel the market growth.
Age-related macular degeneration accounts for 8.7% of all blindness worldwide and is the most common cause of blindness in developed countries particularly in people older than 60 years. The prevalence of AMD is likely to increase as a consequence of exponential population ageing.
There have been significant advances in the management of wet age-related macular degeneration with the introduction of anti-angiogenesis therapy, and patients now have effective treatment options that can prevent blindness and, in many cases, restore vision. However, these treatments are expensive and not available to all patients in many countries. The report explains that growth in the market will be driven by the entry of longer-acting anti-angiogenic therapies and the launch of products for dry AMD and geographic atrophy (GA), which are two forms of advanced disease for which there are no approved therapies. Thus, understanding the burden, population impact and treatments options is essential to develop strategies for adequate health care planning and delivery, which require both precise and modern market estimates.

How this report will benefit you
The report provides a thoughtful understanding into the global age-related macular degeneration market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, PEST analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the macular degeneration industry in any manner.
As the coronavirus disease (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.
To access the data contained in this document please email contactus@visiongain.com
In this brand-new 445-page report you will receive 279 charts- all unavailable elsewhere.
The 445-page Visiongain report provides clear detailed insight into the macular degeneration market. Discover the key trends and development in the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope
. Global macular degeneration and other retinal diseases drug market forecasts from 2021-2031
. This report also breaks down the revenue forecast to 2031 for the global macular degeneration and other retinal diseases drug market by indication, type, product and distribution channel:
. By Indication
- Diabetic Macular Edema
- Diabetic Retinopathy
- Retinal Vein Occlusion
- Others
. By Type
- Wet AMD
- Dry AMD
- Geographic Atrophy
. By Product
- Lucentis
- Eylea
- Avastin
- Visudyne
- Others
. By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Others

This report discusses the market trends and developments of each submarket.
Need industry data? Please contact us today.
. Our study discusses the selected leading companies that are the major players in the macular degeneration (AMD) and other retinal diseases drugs market:
- Novartis AG
- F. Hoffmann-La Roche, Ltd.
- GlaxoSmithKline Pharmaceuticals Ltd.
- Bayer AG
- Pfizer Inc.
- Regeneron Pharmaceuticals
- Bausch & Lomb Incorporated
- Apellis Pharmaceuticals
- Santen Pharmaceuticals
- Alimera Sciences
- AbbVie Inc.
- IVERIC bio, Inc. (Formerly Ophthotech)
- Graybug Vision, Inc.
- Kubota Vision Inc.


Read the full report: https://www.reportlinker.com/p06061829/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001